

Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

FROM DRUG DISCOVERY TO MARKETED PRODUCTS

INVESTMENT HIGHLIGHTS

A pure-play biopharmaceutical company

- Robust and balanced pipeline
- Self-sustaining pipeline from drug discovery to market
- Specialized in endocrinology and oncology

Drug Discovery	Preclinical Trials	Phase 1	Phase 2	Phase 3	Marketed
120,000 compound library	AEZS-115 (endometriosis & urology) AEZS-120 (oncology vaccine) Erk/PI3K inhibitors (oncology) Ghrelin receptor ligands (endocrinology and oncology) AEZS-127 (oncology)	AEZS-112 (oncology) AEZS-130 (endocrinology)	AEZS-108 (endometrial and ovarian cancers) Cetorelix (endometriosis) (BPH in Japan) Ozarelix (BPH, prostate cancer) Perifosine (multiple cancers)	Cetorelix (BPH)	Cetrotide® (in vitro fertilization)
Partners	AEZS-127: Keryx	AEZS-130: Ardana	Cetorelix: Shionogi in Japan Ozarelix: Spectrum in North America and India, Nippon Kayaku in Japan Perifosine: Keryx in North America		Cetrotide®: Merck Serono (World ex-Japan) Nippon Kayaku / Shionogi (Japan)

DRUG DEVELOPMENT PRIORITIES

The two highest priority clinical programs are our lead value driver, cetorelix, for benign prostatic hyperplasia (BPH) and our lead oncology program, AEZS-108, for endometrial and ovarian cancer.

Cetorelix

Cetorelix is a peptide-based active substance (LHRH antagonists) which is currently undergoing Phase 3 clinical trials for treating symptoms associated with BPH. The Phase 3 program will include 1,500 patients in North America and Europe and the results of these trials are expected in 2009.


BPH is a benign enlargement of the prostate gland. Common symptoms of BPH include difficulty urinating, frequent and urgent urination, urinating during night, residual urine in bladder (tendency for infections), bladder overflow, retention of urine and need for surgery. BPH is one of the most common diseases of aging men affecting more than a third of men over 50 years of age and representing a market of \$2.9B in the 7 major markets in 2006 (Source: Decision Resources 2007).

Compared with existing treatments, cetorelix was well tolerated with a low incidence of sexual side effects in Phase 2 studies. It also provided fast and long lasting relief of BPH symptoms.

We thus believe that cetorelix has the potential to offer patients a more convenient approach to BPH management with a higher compliance rate than existing therapies.

AEZS-108

AEZS-108 is a novel targeted approach in a Phase 2 trial for endometrial and ovarian cancer. AEZS-108 is a hybrid molecule composed of a synthetic peptide that carries the well-known chemotherapeutic agent, doxorubicin, to the core of cancerous cells. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by the LHRH receptor-positive tumors. This targeted approach could have less side-effects and be more effective in inhibiting tumor growth than some of the current chemotherapeutics compounds.



2008 MILESTONES

Q2	Q3	Q4
<ul style="list-style-type: none"> - Initiate Phase 3 safety trial with cetorelix in BPH - Initiate QTc study Phase 3 with cetorelix in BPH 	<ul style="list-style-type: none"> - Full recruitment for EU Phase 3 efficacy trial with cetorelix in BPH - Full recruitment for Phase 3 safety trial with cetorelix in BPH - Japanese Phase 2b results with cetorelix in BPH (Shionogi) 	<ul style="list-style-type: none"> - Initiate proof-of-concept trial for ghrelin antagonist - Top-line Phase 2 results with perfosine + radiotherapy - Initiate Phase 2 trial with AEZS-112

Market data as of May 7, 2008	NASDAQ	TSX
Closing price	US\$1.22	C\$1.25
Total shares outstanding	53.2 million	53.2 million
Market capitalization	US\$64.9 million	C\$66.5 million

SELECTED FINANCIAL INFORMATION

(IN MILLIONS OF US\$)

	THREE MONTHS ENDED		FOR YEAR ENDED	
	MARCH 31, 2008	MARCH 31, 2007	DEC. 31, 2007	DEC. 31, 2006
Revenues	9.7	9.2	42.1	38.8
R&D net	13.7	7.9	37.2	25.9
Loss from operations	(14.2)	(8.3)	(34.8)	(23.8)
Cash and short-term investment	38.7	55.5	41.4	60.5

CONTACT

FOR INFORMATION AND TO RECEIVE AN INVESTOR PACKAGE:

Please contact Ginette Vallières
Phone: 418-652-8525
gvallieres@aezsinc.com

Æterna Zentaris Inc.
1405 du Parc-Technologique Blvd.
Québec, Québec, CANADA,
G1P 4P5
www.aezsinc.com

NOTE & DISCLOSURES

This document contains forward-looking statements, which reflect our current expectations regarding future events. Forward-looking statements may include words such as anticipate, believe, could, expect, goal, guidance, intend, may, objective, outlook, plan, seek, should, strive, target and will.

The forward-looking statements involve risks and uncertainties. Results or performances may differ significantly from expectations. For example, the results of current clinical trials cannot be foreseen, nor can changes in policy or actions taken by such regulatory authorities as the US Food and Drug Administration and the Therapeutic Products Directorate of Health Canada, or any other organization responsible for enforcing regulations in the pharmaceutical industry.

Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except as requested by a governmental authority or applicable law.

Updated on May 8, 2008